Generium-Next’s new pharmaceutical manufacturing facility has officially launched at the Alabushevo site within the Skolkovo Innovation Center’s special economic zone Technopolis Moscow. The plant specializes in producing vital and socially significant drugs. Construction of the complex started in 2022 and was completed in October of this year, with investments exceeding 8.5 billion rubles, according to a statement on Moscow’s city portal.
Covering more than 28,000 square meters, the facility is expected to produce up to 5.4 million vials of medicinal products annually. Aleksandr Andryushekin, general director of OOO Generium-Next, stated that the new production capacity will ensure uninterrupted access for patients to advanced therapies. The plant plans to manufacture complex biotechnological drugs for treating orphan and other diseases, including bronchial asthma, idiopathic urticaria, Gaucher’s disease, cystic fibrosis, cardiovascular conditions, as well as rare blood and kidney disorders.
“We intend to produce finished forms not only for generics, which Generium was the first to register in Russia, but also for innovative medicines. Next year, we will begin manufacturing the first Russian-originator drug for Hunter’s disease,” Andryushekin said.
Medicines will be produced using domestically sourced raw materials. Serial production is scheduled to commence by the end of 2026. The company anticipates that once operating at full capacity, Generium-Next will fully meet the demand for orphan drugs across Moscow and the country.
The pharmaceutical cluster within the Technopolis Moscow SEZ is the largest in the capital, currently housing eight manufacturing facilities. The Generium-Next plant is the ninth.